Oxford, UK – 7 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that it has signed a new non-exclusive licence under Oxford BioMedica’s LentiVector® platform technology patents for manufacturing and development services with MolMed S.p.A (“MolMed”) (MLM. MI). A previous retroviral patent agreement between Oxford BioMedica and MolMed has now expired.
John Dawson, CEO of Oxford BioMedica, commented: “This agreement with MolMed is a further endorsement of our dominant patent estate and of our unique LentiVector® platform technology for state-of-the-art bioprocessing and development services. Oxford BioMedica is already a partner for leading companies in the gene and cell therapy sector including Novartis, Sanofi, GSK and Immune Design.”
- Ends -
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips
Tel: +44 (0)20 3709 5700